The consortium which involves eleven partners will “Develop a systems biomedicine approach for risk identification, prevention and treatment of type 2 diabetes -T2DSystems”.
A research consortium in which Professor Anna Gloyn is a member has been awarded EU funding of €5.99 million as part of the Horizon 2020 Research and Innovation Framework Progamme.